Terumo Corporation · TSE:4543
Terumo — Investor Presentation (May 2016)
9 slides from Terumo's investor presentation, May 10, 2016
Slide 1: "Roadmap to FY16" and Beyond
"Roadmap to FY16" and Beyond Terumo Corporation President and CEO Yutaro Shintaku May 10, 10 2016
Slide 2: FY15: Achieved Record-high Profits
FY15: Achieved Record‐high Profits Net Sales 525 0 BJPY 525.0 Operating Income 101.9 BJPY (Excl. Amortization) Marked a Operating Income 81.7 BJPY record high of both sales Ordinary Income 73.1 BJPY andd profit fit Net Income 50.7 BJPY © Terumo Corporation 2016/5/10 2/9
Slide 3: Achieved Target of "Roadmap to FY16" a Year Ahead of Schedule
Achieved Target of "Roadmap to FY16" a Year Ahead of Schedule Operating margin excluding amortization Actual results "Roadmap to FY16" 20% 20%* 20% 19% 18% 18% 18% 17% 17% 17% Assumed exchange rate when starting 16% "Roadmap to FY16" USD=100JPY, EUR=140JPY 15% FY13 FY14 FY15 FY16 Target © Terumo Cor
Slide 4: FY13-15: Performance Improvement by Business Segment
FY13‐15: Performance Improvement by Business Segment Cardiac and Vascular: Drove the group's growth and increase in profit General Hospital: Toward steady recovery through downsizing low profit business Blood Management: Minimized the impact of price declines Sales (billion yen) Business Profi
Slide 5: FY13-15: Continuous Growth in Overseas Business
FY13‐15: Continuous Growth in Overseas Business Expand business in highly profitable and growing markets: US and China Infrastructure development in growing market: India Downsizes low profit business in Europe and Latin America: Rises resistance to FX fluctuations Sales CAGR (billion yen) 15%
Slide 6: Environmental Changes
Environmental Changes Macro‐ Prolonged slow growth economyy FX fluctuation, financial risk Expansion in medical beneficiaries, increase in demand due to Healthcare aging society environment Required higher medical efficiency Healthcare integration and oligopolization mainly in US Competiti
Slide 7: Continuing Large-scaled Consolidation in Med-tech Market
Continuing Large‐scaled Consolidation in Med‐tech Market 2014 2016 Company Sales (BUSD) Company Sales (BUSD) 1 1 26.8 2 2 26.6 3 3 15 5 15.5 4 4 15.3 5 5 11 6 11.6 6 6 10.5 7 7 9.0 8 8 7.7 9 9 7.1 10 10 7.1 11 11 4.9 12 12 Terumo 47 4.7 13 Terumo © Terumo Corporation 2016/5/10 7/9
Slide 8: Discussion Points of New Growth Strategy
Discussion Points of New Growth Strategy "Sustainable and Profitable Growth" is always grass roots. • Expands p global g presence p in priority p y areas In Japan, maintain the company's top level position firmly • Respond the increase in healthcare demands driven by aging society • Translate th
Slide 9: IR Contact
IR Contact Terumo Corporation Corporate Communication (IR) Dept. E‐mail: [email protected] Among the information that Terumo discloses, the forward‐looking statements including financial projections are based upon our assumptions using information available to us at the time and are not i